Clinical Trials Logo

Clinical Trial Summary

Individuals with migraine have impaired cognitive function and worse autonomic function compared to individuals without migraine. Objective: To evaluate the autonomic function and cognition in young individuals with migraine compared to healthy individuals without migraine. Methods: Cross-sectional study will be carried out at University of Fortaleza with individuals with previous migraines diagnoses and healthy volunteers without migraines. Volunteers of both sexes, aged between 18 and 60 years, clinically diagnosed with migraine or not, who have not undergone any type of drug treatment for at least three months and who accept to participate in the research will be enrolled in the research. Individuals who have comorbidities such as hypertension and Diabetes mellitus (type I and II), respiratory, cardiac and/or chronic vascular diseases, have suffered any significant facial trauma, have a cognitive problem or dysfunction associated with cognition, or have suffered any episode of stroke or transient ischemic attack prior to conducting this research will not be enrolled. Participants will be assessed through cognitive tests, and autonomic function such as Neck Disability Index, Migraine Disability Assessment Questionnaire, Stroop Colo test, digit symbol substitution test, Addenbrooke's cognitive examination, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A and B and reaction time test and by MindWave Mobile® devices and Polar V800®.


Clinical Trial Description

The sympathetic nervous system is responsible for responding to stressful situations with involuntary actions, which will increase the neuronal activity in order to maintain body homeostasis. Stress is one of the most common causes of migraines. When it occurs for a prolonged period, there will be an over-stimulation of the sympathetic nervous system that will lead to dysautonomia, generating the rapid consumption of the neurotransmitter norepinephrine at the same time that adenosine, dopamine. It is believed that before the headache, the levels of norepinephrine are elevated, causing a vasoconstriction of extracranial vascularization, followed by a vasodilation resulting from the release of the other hormones previously mentioned, thus instituting the painful phase of migraine. Thus, migraine acts on the vascular system through changes in its homeostasis, predisposing the occurrence of future ischemic and/or hemorrhagic episodes to the brain and cardiac levels. The disruption of this system with the multifactorial mechanisms of migraine manifestation can then result in an increased risk of coronary heart disease and other changes in cardiac functioning, acquiring highly harmful potential for the human body. The interest in this study started in view of the numerous uncertainties within the scientific sphere regarding the possible systemic impacts caused by migraines after detailed research on the subject. The same becomes relevant, as it will contribute to the development of knowledge about headaches. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04272229
Study type Interventional
Source Fortaleza University
Contact
Status Completed
Phase N/A
Start date January 15, 2020
Completion date December 15, 2020

See also
  Status Clinical Trial Phase
Completed NCT01432379 - BOTOX® Prophylaxis in Patients With Chronic Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05048914 - Migraine Abortive Treatment
Completed NCT03662295 - Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Completed NCT02766517 - Biomarker Study in Participants With Migraine Early Phase 1
Completed NCT00963937 - Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents Phase 3
Not yet recruiting NCT03632928 - Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
Completed NCT02559895 - A Multicenter Assessment of ALD403 in Frequent Episodic Migraine Phase 3
Completed NCT01435941 - Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine N/A
Completed NCT00743015 - Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks Phase 1
Completed NCT01376141 - Drug Use Investigation for IMIGRAN Tablet N/A
Completed NCT02183688 - Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients Phase 3
Completed NCT06061588 - "Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches" N/A
Completed NCT03588364 - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine N/A
Completed NCT04091321 - Association Between Chronic Headache and Back Pain With Childbirth
Completed NCT00385008 - TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine Phase 3
Active, not recruiting NCT05888298 - Proximal and Distal Approach GON RFT in Migraine N/A
Completed NCT03435185 - Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients N/A
Recruiting NCT06459635 - Migraine Attack Pain Phase Prediction Study
Completed NCT02565186 - An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine Phase 3